Caixia Li

机构：Sun Yat-sen University, Eighth Affiliated Hospital of Sun Yat-sen University · ORCID：0000-0002-8170-432X

发表论文 141 篇 · 总被引 2045 次 · h-index 28

代表论文

• Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (2025 · Nature Cancer · 被引 52)
• Disparities in hepatitis B virus healthcare service access among marginalised poor populations: a mixed-method systematic review (2024 · Infectious Diseases of Poverty · 被引 26)
• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 20)
• Unveiling the Potential of Large Language Models in Transforming Chronic Disease Management: Mixed Methods Systematic Review (2025 · Journal of Medical Internet Research · 被引 20)
• Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study (2025 · 癌症：英文版 · 被引 14)
• IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer (2024 · BMC Medicine · 被引 13)